A Phase 2a Double-Blind, Dose-optimizing Study to Evaluate the Immunogenicity of Hantaan/Puumala Virus DNA Vaccine Administered to Healthy Adult Volunteers by Electroporation for Prevention of Hemorrhagic Fever With Renal Syndrome
Latest Information Update: 12 Apr 2021
At a glance
- Drugs PWRG-HTN-M(co)/pWRG-PUUV-M(s2) (Primary)
- Indications Hantaan virus infections; Puumala virus infections; Viral haemorrhagic fevers
- Focus Pharmacodynamics
- 01 Oct 2020 Status changed from active, no longer recruiting to completed.
- 18 Mar 2019 Planned End Date changed from 1 Mar 2019 to 31 Jul 2019.
- 02 May 2018 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.